Syngene International has announced that they have completed a deal through which Syngene has purchased assets of Strand Life Sciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team. Financial details of the deal were not disclosed.
Commenting on this development, Jonathan Hunt, Chief Executive Officer, Syngene International said, "Given the vast volumes of genetic material sequence data that is being generated globally, there is an increasing focus on biological information management and data analytics in drug discovery and development. Syngene is constantly looking for new opportunities to expand its service offerings and plans to expand into areas such as NGS, translational R&D, predictive toxicology and pre-emptive target validation services, all of which require strong bioinformatics capabilities. We believe Strand's bioinformatics platforms not only complement our existing integrated service platforms but will also meet our customers growing needs for bioinformatics and data analytic support."
Chairman and Managing Director of Strand Life Sciences, Dr. Vijay Chandru, added "Strand is glad that the deal with Syngene gives it access to technologies from Strand to form part of its integrated discovery service offerings. This transaction is alsoPutting Science to Work key step for Strand to focus its energies on personalized medicine through clinical applications of all its genomics technologies."
This deal gives Syngene access to Strand's patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratory-based experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for next-generation sequencing data.